Vor Biopharma Inc. Company Profile
NASDAQ: VORHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 2:21 PM ET
Vor Biopharma at a glance
Vor Biopharma Inc. (NASDAQ: VOR) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Boston, MA. Vor Biopharma is led by Dr. Jean-Paul Kress M.D. and employs about 76 people. The company's shares have traded publicly since 2021.
At a market capitalization of $1.11 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001817229, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Vor Biopharma do?
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Vor Biopharma Inc.
- Ticker
- NASDAQ: VOR
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Jean-Paul Kress M.D.
- Employees
- 76
- Headquarters
- 500 Boylston Street, Boston, MA, United States
- Phone
- 617 655 6580
- Website
- vorbio.com
- IPO year
- 2021
- Market cap
- $1.11B
- SEC CIK
- 0001817229
Companies similar to Vor Biopharma
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMTXImmatics N.V. | 7.39 | -0.81% | $1.12B | vs VOR |
| MGTXMeiraGTx Holdings plc | 10.54 | -2.59% | $1.01B | vs VOR |
| REPLReplimune Group Inc. | 13.18 | -0.15% | $1.24B | vs VOR |
| CGEMCullinan Therapeutics Inc. | 15.57 | -0.42% | $956.59M | vs VOR |
| ODTXOdyssey Therapeutics Inc. | 18.16 | +0.41% | $872.50M | vs VOR |
| GLUEMonte Rosa Therapeutics Inc. | 10.19 | +0.20% | $869.34M | vs VOR |
| INBXInhibrx Biosciences Inc. | 92.14 | -1.31% | $1.36B | vs VOR |
| SLBTSL Science Holding Limited | 1.51 | 0.00% | $846.75M | vs VOR |